Oseltamivir in pregnancy and birth outcomes
| Autor: | Nickolaj R. Kristensen, Brigitta Monz, Henrik Toft Sørensen, Barry Clinch, A. Kenwright, Vera Ehrenstein |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Pediatrics
Influenza Human/drug therapy Epidemiology Denmark Prenatal Exposure Delayed Effects/chemically induced Prevalence Infant Newborn Diseases chemistry.chemical_compound Congenital Abnormalities/epidemiology 0302 clinical medicine Pregnancy 030212 general & internal medicine Registries Pregnancy Complications Infectious Oseltamivir/therapeutic use education.field_of_study 030219 obstetrics & reproductive medicine Pregnancy Outcome Infectious Diseases Premature Birth/epidemiology Infant Newborn Diseases/epidemiology Prenatal Exposure Delayed Effects Premature Birth Apgar score Female Research Article Adult medicine.medical_specialty Oseltamivir Population Pregnancy Outcome/epidemiology lcsh:Infectious and parasitic diseases Congenital Abnormalities 03 medical and health sciences Young Adult Influenza Human medicine Humans lcsh:RC109-216 education business.industry Pregnancy Complications Infectious/drug therapy Infant Newborn Odds ratio medicine.disease Denmark/epidemiology chemistry Propensity score matching H1N1 influenza business |
| Zdroj: | BMC Infectious Diseases Ehrenstein, V, Kristensen, N R, Monz, B U, Clinch, B, Kenwright, A & Sørensen, H T 2018, ' Oseltamivir in pregnancy and birth outcomes ', BMC Infectious Diseases, vol. 18, no. 1, pp. 519 . https://doi.org/10.1186/s12879-018-3423-z BMC Infectious Diseases, Vol 18, Iss 1, Pp 1-10 (2018) |
| ISSN: | 1471-2334 |
| Popis: | Background Prenatal exposure to influenza or fever is associated with risk of congenital malformations. Oseltamivir is used to treat influenza and to provide post-exposure prophylaxis. We examined the association between oseltamivir use during pregnancy and birth outcomes. Methods This was a nationwide registry-based prevalence study with individual level data linkage, in a setting of universal health care access. We included all recorded pregnancies in Denmark in 2002–2013, and used data from population registries to examine associations between dispensings for oseltamivir during pregnancy (first trimester, second/third trimester, none) and congenital malformations, foetal death, preterm birth, foetal growth, and low 5-min Apgar score. Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were computed using propensity score matching. Results The study included 946,176 pregnancies. Of these, 449 had first-trimester exposure and 1449 had second/third-trimester exposure to oseltamivir. Adjusted ORs following first-trimester exposure were 0.94 (95% CI 0.49 to 1.83) for any major congenital malformation and 1.75 (95% CI 0.51 to 5.98) for congenital heart defects, based on 7 exposed cases. The association with congenital heart defects was present for etiologically implausible exposure periods and for known safe exposures. There was no evidence of an association between prenatal exposure to oseltamivir and any of the other birth outcomes assessed. Conclusions The study does not provide evidence of risk associated with oseltamivir treatment additional to that associated with influenza infection. Electronic supplementary material The online version of this article (10.1186/s12879-018-3423-z) contains supplementary material, which is available to authorized users. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink